Researchers Find Which GLP-1 Treatment Delivers the Greatest Weight Loss

A recent study from the University of Georgia found that the weight-loss drug tirzepatide is more effective than semaglutide and liraglutide for individuals without diabetes. Researchers from the university’s pharmacy college analysed data from 15 large clinical trials involving more than 14,000 participants. They published their findings in the journal Obesity. This is the first study to compare all three approved weight-loss drugs in a group made up entirely of non-diabetic adults. The findings give doctors clearer evidence when choosing the most suitable treatment.

The differences in weight loss were substantial. Patients taking the highest weekly dose of tirzepatide lost more than 20% of their body weight on average. Those using semaglutide lost about 15%. Participants taking liraglutide lost around 8%. The medications also differ in dosing schedules. Tirzepatide and semaglutide require one injection each week. In contrast, patients must inject liraglutide every day. Weekly treatment may help people stay on therapy for longer.

Tirzepatide delivers stronger results because it targets two hormones instead of one. Semaglutide and liraglutide mimic the GLP-1 hormone. This hormone reduces appetite and slows digestion. Tirzepatide activates both GLP-1 and GIP. These hormones work together to increase feelings of fullness. As a result, patients often achieve greater weight loss.

Doctors prescribe tirzepatide under two brand names. They use Zepbound for chronic weight management. They prescribe Mounjaro for type 2 diabetes. Both medicines require a doctor’s prescription. Researchers also assessed a high-dose oral version of semaglutide. They found that the daily tablet performs about as well as the weekly injection. However, it still falls short of the weight loss seen with injectable tirzepatide.

Despite its greater effectiveness, tirzepatide did not produce more side effects than the other medicines. Researchers carefully assessed how patients tolerated each treatment. Nausea and other stomach problems remain common with all three drugs. Even so, people taking tirzepatide did not report these effects more often than those using the other medications. This finding strengthens its role as a leading weight-loss treatment.

The researchers also highlighted several important limitations. They did not examine what happens after patients stop treatment. Previous research shows that many people regain much of the weight they lose after discontinuing these medicines. For this reason, doctors increasingly treat obesity as a long-term condition. Patients often need ongoing care and support. Doctors should discuss long-term treatment plans before prescribing these medications. Cost, insurance coverage, and medical history also influence the best treatment choice for each patient.